This paper explains a comprehensive and systematic approach to evaluate drug development projects and technology platforms, using an augmented version of net present value (NPV). The benefits of financial models for value-driven project and portfolio management, licensing negotiations and investors' decisions are discussed.
No takes yet. Share an insight, caveat, or question.
Bode-Greuel et al. (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: